Summary: In 1,145 patients with obesity-related HFpEF (BMI ≥30, LVEF ≥45%) with NYHA class II-IV symptoms, semaglutide 2.4 mg subcutaneous weekly for 52 weeks significantly improved NYHA functional class (32.6% improved ≥1 class), with consistent KCCQ and physical function improvements across baseline NYHA categories compared to matching placebo, with similar weight reduction (~8%) regardless of baseline NYHA class and fewer patients experiencing deterioration. PICO Description Population 1,145 patients with obesity-related HFpEF (BMI ≥30, LVEF ≥45%), NYHA class II-IV. Intervention Semaglutide 2.4 mg subcutaneous weekly for 52 weeks, titrated per standard protocol. Comparison Matching placebo weekly for 52 weeks, double-blind randomized.…
Author: Hormone Insight Editorial Team
Read More
Summary: In adults with type 2 diabetes and chronic kidney disease on stable ACE inhibitor or ARB therapy, semaglutide 1.0 mg once weekly reduced the primary composite kidney outcome by 24%, all-cause mortality by 20%, and major cardiovascular events by 18% compared with placebo, with fewer serious adverse events. The trial was stopped early for efficacy. PICO Summary ElementDetailPopulationAdults with type 2 diabetes and CKD (eGFR 25–75 ml/min/1.73 m², UACR >100–5,000 mg/g) on stable ACEi/ARB (n=3,533).InterventionSemaglutide 1.0 mg subcutaneous weekly for a median of 3.4 years.ComparisonMatching placebo weekly for the same duration.OutcomePrimary kidney composite reduced 24% (HR 0.76; 0.66–0.88; P=0.0003).…
Summary: In 1,145 patients with obesity-related HFpEF (BMI ≥30, LVEF ≥45%) from pooled STEP-HFpEF trials, stratified by baseline NT-proBNP tertiles, semaglutide 2.4 mg subcutaneous weekly for 52 weeks significantly reduced NT-proBNP, with KCCQ improvements greatest in highest NT-proBNP tertile (up to 11.9 points) compared to matching placebo, with consistent weight loss (~8%) across all NT-proBNP tertiles regardless of cardiac disease severity. PICO Description Population 1,145 patients with obesity-related HFpEF (BMI ≥30, LVEF ≥45%), stratified by NT-proBNP tertiles. Intervention Semaglutide 2.4 mg subcutaneous weekly for 52 weeks. Comparison Matching placebo weekly, double-blind. Outcome NT-proBNP reduced. KCCQ up to +11.9 in highest…
Summary: In adults with type 2 diabetes (n=1,879) from SURPASS-2 Phase 3 trial, once-weekly tirzepatide (5, 10, or 15 mg) for 40 weeks demonstrated significantly greater improvements in beta-cell function (C-peptide, proinsulin) and insulin sensitivity, with superior HbA1c reduction (2.1-2.4% vs 1.9%) and weight loss (11-13 kg vs 9.6 kg) compared to semaglutide 1.0 mg weekly, with consistent benefits regardless of baseline beta-cell function or insulin resistance status. PICO Description Population Adults with T2D (n=1,879) from 128 sites in 8 countries in SURPASS-2 trial. Intervention Tirzepatide 5, 10, or 15 mg subcutaneous weekly for 40 weeks. Comparison Semaglutide 1.0 mg…
Summary: In adults from pooled SURPASS-1, -2, -3 trials (n=3,792), stratified by early-onset T2D (diagnosed <40 years) vs later-onset (≥40 years), tirzepatide (dual GIP/GLP-1 agonist) for 40-52 weeks achieved comparable improvements in both groups: HbA1c -2.6% vs -2.4%, weight -14 kg vs -13 kg, waist circumference -10 cm, triglycerides -26% vs -24%, SBP -6 vs -7 mmHg compared to later-onset T2D outcomes under identical trial conditions, with robust efficacy regardless of age at diagnosis despite worse baseline metabolic profiles in early-onset patients. PICO Description Population Adults from SURPASS-1, -2, -3 (n=3,792), stratified by early-onset (<40y) vs later-onset (≥40y) T2D. Intervention…
Summary: In overweight/obese adults with type 2 diabetes and NAFLD, combination semaglutide plus empagliflozin for 52 weeks produced significantly greater liver fat reduction (CAP score), liver enzyme improvements (ALT, AST, GGT), and enhanced glycemic/lipid control compared to monotherapy with either semaglutide alone or empagliflozin alone, with no unexpected adverse signals supporting the combination approach. PICO Description Population Overweight/obese adults with type 2 diabetes and NAFLD. Intervention Combination semaglutide (GLP-1 RA) plus empagliflozin (SGLT2i) for 52 weeks. Comparison Monotherapy with either semaglutide alone or empagliflozin alone for 52 weeks. Outcome Greater liver fat reduction (CAP), improved liver enzymes, enhanced HbA1c and…
Summary: In 1,145 adults with obesity-related HFpEF (BMI ≥30, LVEF ≥45%, NYHA II-IV) pooled from STEP-HFpEF and STEP-HFpEF DM trials, semaglutide 2.4 mg subcutaneous weekly for 52 weeks significantly improved KCCQ-CSS (+7.5 points, P<0.0001), body weight (-8.4%, P<0.0001), 6MWD (+17.1m, P<0.0001), and CRP (-36%, P<0.0001) compared to matching placebo, with fewer serious adverse events (161 vs 301) and consistent benefits regardless of diabetes status. PICO Description Population 1,145 adults with obesity-related HFpEF (BMI ≥30, LVEF ≥45%, NYHA II-IV) from pooled trials. Intervention Semaglutide 2.4 mg subcutaneous weekly for 52 weeks. Comparison Matching placebo weekly, double-blind. Outcome KCCQ +7.5, weight -8.4%,…
Summary: In 616 adults with HFpEF (EF ≥45%), obesity (BMI ≥30), and type 2 diabetes, semaglutide 2.4 mg subcutaneous weekly for 52 weeks significantly improved KCCQ-CSS (+13.7 vs +6.4 points, difference 7.3, P<0.001), weight (-9.8% vs -3.4%), 6MWD, and CRP levels compared to matching placebo, with fewer serious adverse events (17.7% vs 28.8%). PICO Description Population 616 adults with HFpEF (EF ≥45%), obesity (BMI ≥30), and type 2 diabetes. Intervention Semaglutide 2.4 mg subcutaneous weekly for 52 weeks. Comparison Matching placebo weekly for 52 weeks. Outcome KCCQ +7.3 difference. Weight -9.8% vs -3.4%. Serious AEs 17.7% vs 28.8%. Clinical Context…
A phase 1 clamp trial shows tirzepatide improves beta-cell function and insulin sensitivity more than semaglutide, explaining its glucose-lowering. PICO summary and commentary.
A clinical guideline update on the prevention or delay of diabetes and associated comorbidities was published in January 2025 by the American Diabetes Association (ADA) Professional Practice Committee. These guidelines, published in Diabetes Care (2025;48(Suppl. 1):S50–S58).